PTJ
SRPT icon

Paul Tudor Jones’s Sarepta Therapeutics SRPT Stock Holding History

Paul Tudor Jones’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,000
Closed -$387K – 4236
2025
Q4 		$387K Sell
18,000
-155,700
-90% -$3.28M ﹤0.01% 2873
2025
Q3 		$3.35M Sell
173,700
-48,800
-22% -$870K 0.01% 1463
2025
Q2 		$3.8M Buy
222,500
+212,300
+2,081% +$9.06M 0.01% 1249
2025
Q1 		$651K Buy
+10,200
New +$1.07M ﹤0.01% 2108

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Paul Tudor Jones's SRPT Position: Q4 2025 in Review

Paul Tudor Jones sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 152,803 shares — an estimated $3.22M sold.

Paul Tudor Jones first reported a position in SRPT in Q3 2015 and held it in 17 quarters. The position peaked at $13.3M in Q3 2016. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Paul Tudor Jones reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 152,803 Sarepta Therapeutics shares in Q4 2025, an estimated $3.22M.
  • Paul Tudor Jones first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 17 quarters.
  • Paul Tudor Jones's Sarepta Therapeutics position peaked at $13.3M in Q3 2016.
  • 346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Tudor Investment Corp's 13F filing for Q4 2025, filed 17 Feb 2026.